TY - JOUR
T1 - European Association of Urology Guidelines on Sexual and Reproductive Health—2021 Update
T2 - Male Sexual Dysfunction[Formula presented]
AU - Salonia, Andrea
AU - Bettocchi, Carlo
AU - Boeri, Luca
AU - Capogrosso, Paolo
AU - Carvalho, Joana
AU - Cilesiz, Nusret Can
AU - Cocci, Andrea
AU - Corona, Giovanni
AU - Dimitropoulos, Kostantinos
AU - Gül, Murat
AU - Hatzichristodoulou, Georgios
AU - Jones, T. Hugh
AU - Kadioglu, Ates
AU - Martínez Salamanca, Juan Ignatio
AU - Milenkovic, Uros
AU - Modgil, Vaibhav
AU - Russo, Giorgio Ivan
AU - Serefoglu, Ege Can
AU - Tharakan, Tharu
AU - Verze, Paolo
AU - Minhas, Suks
N1 - Publisher Copyright:
© 2021 European Association of Urology
PY - 2021/9
Y1 - 2021/9
N2 - Context: The present summary of the European Association of Urology (EAU) guidelines is based on the latest guidelines on male sexual health published in March 2021, with a last comprehensive update in January 2021. Objective: To present a summary of the 2021 version of the EAU guidelines on sexual and reproductive health. Evidence acquisition: A literature review was performed up to January 2021. The guidelines were updated, and a strength rating for each recommendation was included based on either a systematic review of the evidence or a consensus opinion from the expert panel. Evidence synthesis: Late-onset hypogonadism is a clinical condition in the ageing male combining low levels of circulating testosterone and specific symptoms associated with impaired hormone production and/or action. A comprehensive diagnostic and therapeutic work-up, along with screening recommendations and contraindications, is provided. Erectile dysfunction (ED) is the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance. Along with a detailed basic and advanced diagnostic approach, a novel decision-making algorithm for treating ED in order to better tailor therapy to individual patients is provided. The EAU guidelines have adopted the definition of premature ejaculation (PE), which has been developed by the International Society for Sexual Medicine. After the subtype of PE has been defined, patient's expectations should be discussed thoroughly and pharmacotherapy must be considered as the first-line treatment for patients with lifelong PE, whereas treating the underlying cause must be the initial goal for patients with acquired PE. Haemospermia is defined as the appearance of blood in the ejaculate. Several reasons of haemospermia have been acknowledged; the primary goal over the management work-up is to exclude malignant conditions and treat any other underlying cause. Conclusions: The 2021 guidelines on sexual and reproductive health summarise the most recent findings, and advise in terms of diagnosis and treatment of male hypogonadism and sexual dysfunction for their use in clinical practice. These guidelines reflect the multidisciplinary nature of their management. Patient summary: Updated European Association of Urology guidelines on sexual and reproductive health are presented, addressing the diagnosis and treatment of the most prevalent conditions in men. Patients must be fully informed of all relevant diagnostic and therapeutic options and, together with their treating physicians, decide on optimal personalised management strategies.
AB - Context: The present summary of the European Association of Urology (EAU) guidelines is based on the latest guidelines on male sexual health published in March 2021, with a last comprehensive update in January 2021. Objective: To present a summary of the 2021 version of the EAU guidelines on sexual and reproductive health. Evidence acquisition: A literature review was performed up to January 2021. The guidelines were updated, and a strength rating for each recommendation was included based on either a systematic review of the evidence or a consensus opinion from the expert panel. Evidence synthesis: Late-onset hypogonadism is a clinical condition in the ageing male combining low levels of circulating testosterone and specific symptoms associated with impaired hormone production and/or action. A comprehensive diagnostic and therapeutic work-up, along with screening recommendations and contraindications, is provided. Erectile dysfunction (ED) is the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance. Along with a detailed basic and advanced diagnostic approach, a novel decision-making algorithm for treating ED in order to better tailor therapy to individual patients is provided. The EAU guidelines have adopted the definition of premature ejaculation (PE), which has been developed by the International Society for Sexual Medicine. After the subtype of PE has been defined, patient's expectations should be discussed thoroughly and pharmacotherapy must be considered as the first-line treatment for patients with lifelong PE, whereas treating the underlying cause must be the initial goal for patients with acquired PE. Haemospermia is defined as the appearance of blood in the ejaculate. Several reasons of haemospermia have been acknowledged; the primary goal over the management work-up is to exclude malignant conditions and treat any other underlying cause. Conclusions: The 2021 guidelines on sexual and reproductive health summarise the most recent findings, and advise in terms of diagnosis and treatment of male hypogonadism and sexual dysfunction for their use in clinical practice. These guidelines reflect the multidisciplinary nature of their management. Patient summary: Updated European Association of Urology guidelines on sexual and reproductive health are presented, addressing the diagnosis and treatment of the most prevalent conditions in men. Patients must be fully informed of all relevant diagnostic and therapeutic options and, together with their treating physicians, decide on optimal personalised management strategies.
KW - Ejaculatory disorders
KW - Erectile dysfunction
KW - Guidelines
KW - Haemospermia
KW - Hypogonadism
KW - Male
KW - Premature ejaculation
KW - Sexual dysfunction
KW - Testosterone
UR - http://www.scopus.com/inward/record.url?scp=85108790896&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2021.06.007
DO - 10.1016/j.eururo.2021.06.007
M3 - Review article
C2 - 34183196
AN - SCOPUS:85108790896
SN - 0302-2838
VL - 80
SP - 333
EP - 357
JO - European Urology
JF - European Urology
IS - 3
ER -